Results from the SORCE clinical trial to assess sorfenib as an adjuvant treatment for renal cell carcinoma (RCC) at intermediate or high risk of relapse were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend.
As for previous large randomised phase 3 clinical trials (ASSURE, PROTECT, and ATLAS) to assess adjuvant VEGF tyrosine kinase inhibitors in patients with resected renal cell carcinoma (RCC), the SORCE trial failed to meet its primary endpoint. Only S-TRAC met the primary endpoint of improvement in disease-free survival.
In summary, up to 3 years of sorafenib treatment did not improve disease-free or overall survival in patients with resected RCC at intermediate or high risk of relapse compared to placebo. Active surveillance remains the global standard of care for patients at intermediate or high risk of recurrence following nephrectomy.